Singapore: Mylan Specialty, a subsidiary of Mylan, and Pfizer entered into a license agreement, under which Pfizer will obtain the exclusive rights from Mylan Seiyaku to market and sell EpiPen injection 0.3/0.15mg in Japan. The financial terms of the agreement are yet to be disclosed.

These products, known in the US as EpiPen (epinephrine) 0.3mg and EpiPen Jr (epinephrine) 0.15mg auto-injectors, are for self-administration and are used for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise or unknown triggers. EpiPen injection is the only approved epinephrine auto-injector in Japan.

Ms Heather Bresch, CEO, Mylan, said that, "We are very excited to extend our partnership with Pfizer to this important market. Last year, we announced that the Japanese Ministry of Health, Labour and Welfare approved National Health Insurance price listing for EpiPen Injection."

"We have built on this positive momentum by recently launching our next-generation EpiPen Injection in Japan. We look forward to achieving success with Pfizer as our partner that furthers our commitment to better serve the people of Japan who suffer from life-threatening allergies," she said.

Mr Ichiro Umeda, president, Pfizer Japan, said that, "Pfizer and Mylan share a deep commitment to serve the people of Japan who are at risk for anaphylaxis. This agreement will help us to better address this important public health issue in Japan, from improving awareness and preparedness, to expanding access to treatment, through Pfizer's existing commercial infrastructure and market expertise."